These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34994615)

  • 1. Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.
    Pruis MA; Paats MS; Geurts WRR; Dubbink HJ; Dingemans AC
    JCO Precis Oncol; 2021 Nov; 5():849-853. PubMed ID: 34994615
    [No Abstract]   [Full Text] [Related]  

  • 2. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
    Jin W; Shan B; Liu H; Zhou S; Li W; Pan J; Lin L; Hu D; Pan Y
    J Thorac Oncol; 2019 Jul; 14(7):e137-e139. PubMed ID: 31055074
    [No Abstract]   [Full Text] [Related]  

  • 3. ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
    Guisier F; Piton N; Salaun M; Thiberville L
    Clin Lung Cancer; 2019 Nov; 20(6):e593-e596. PubMed ID: 31395437
    [No Abstract]   [Full Text] [Related]  

  • 4. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
    Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
    Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
    Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
    Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
    J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.
    Klempner SJ; Borghei A; Hakimian B; Ali SM; Ou SI
    J Thorac Oncol; 2017 Jan; 12(1):152-156. PubMed ID: 27693535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
    Kauffmann-Guerrero D; Kahnert K; Kumbrink J; Syunyaeva Z; Tufman A; Huber RM
    Clin Lung Cancer; 2019 Jan; 20(1):59-62. PubMed ID: 30341016
    [No Abstract]   [Full Text] [Related]  

  • 10. Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
    Schrock AB; Lai A; Ali SM; Miller VA; Raez LE
    J Thorac Oncol; 2017 Jul; 12(7):e89-e90. PubMed ID: 28629543
    [No Abstract]   [Full Text] [Related]  

  • 11. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
    Ding G; Wang J; Ding P; Wen Y; Yang L
    Cancer Biol Ther; 2019; 20(6):837-842. PubMed ID: 30744539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
    Wang Y; Chen Z; Han X; Li J; Guo H; Shi J
    Oncologist; 2021 Mar; 26(3):178-181. PubMed ID: 33000474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer.
    Sun TY; Niu X; Chakraborty A; Neal JW; Wakelee HA
    J Thorac Oncol; 2019 Feb; 14(2):e21-e24. PubMed ID: 30217491
    [No Abstract]   [Full Text] [Related]  

  • 14. MET-Mutated NSCLC with Major Response to Crizotinib.
    Mendenhall MA; Goldman JW
    J Thorac Oncol; 2015 May; 10(5):e33-e34. PubMed ID: 25898965
    [No Abstract]   [Full Text] [Related]  

  • 15. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
    Parsons BM; Meier DR; Richmond CS; Gurda GT; Lofgren KA; Burkard ME; Deming DA; Kenny PA
    Clin Breast Cancer; 2020 Aug; 20(4):e433-e438. PubMed ID: 32234363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With
    Hur JY; Ku BM; Shim JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    In Vivo; 2020; 34(3):1399-1406. PubMed ID: 32354937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
    Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
    Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.